Amgen earnings preview: Will AMGN's streak of EPS beats continue in Q1?
JHVEPhoto/iStock Editorial via Getty Images

Amgen (NASDAQ:AMGN) is scheduled to announce Q1 2023 financial results on Thursday, April 27, after market close.
The consensus EPS estimate is $3.85 and the consensus revenue estimate is $6.18B.
Over the last two years, the biotech has had seven EPS beats and six revenue beats.
Over the last three months, annual EPS estimates have seen two upward revisions and 10 downward ones. Revenue estimates have seen three upward revisions and eight downward ones.
In Q4 2022, Amgen's (AMGN) EPS came inline while revenue was a slight beat. At the time of the earnings release, the company issued 2023 financial guidance with both EPS and revenue estimates within analyst expectations.
Recently, a news outlet reported that Amgen's (AMGN) $28B acquisition of Horizon Therapeutics (HZNP) is on track to close in the first half of the year. 
In Q1, Amgen (AMGN) instituted two rounds of job cuts. The first, in January, included 300 positions, while the second, in March, was for ~450 jobs. 
More on Amgen
Is Amgen A Buy Ahead Of The Q1 Results?
Amgen Has Long-Term Staying Power
Amgen: Revenue Growth Potentials And Financial Performance
Amgen: Questioning The Horizon Therapeutics Acquisition
Amgen Announces More Layoffs - Why I'd Buy This Dip